HighVista Strategies’s MoonLake Immunotherapeutics MLTX Stock Holding History

HighVista Strategies’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.66M	Sell	187,946 -6,009	-3%	-$109K	0.83%	39
2026 Q1	$3.62M	Buy	+193,955	New	+$3.21M	1%	26
2025 Q4	–	Sell	-19,059	Closed	-$137K	–	167
2025 Q3	$137K	Sell	19,059 -1,894	-9%	-$98.7K	0.03%	148
2025 Q2	$989K	Sell	20,953 -22,588	-52%	-$920K	0.36%	109
2025 Q1	$1.7M	Hold	43,541	–	–	0.66%	52
2024 Q4	$2.36M	Hold	43,541	–	–	0.88%	32
2024 Q3	$2.2M	Buy	43,541 +1,292	+3%	+$60.5K	0.76%	39
2024 Q2	$1.86M	Sell	42,249 -17,520	-29%	-$742K	0.68%	44
2024 Q1	$3M	Hold	59,769	–	–	1.07%	26
2023 Q4	$3.61M	Hold	59,769	–	–	1.31%	23
2023 Q3	$3.41M	Sell	59,769 -69,953	-54%	-$3.86M	1.58%	14
2023 Q2	$6.62M	Buy	129,722 +7,521	+6%	+$202K	3.03%	2
2023 Q1	$2.61M	Buy	+122,201	New	+$2.05M	2.13%	12

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighVista Strategies's MLTX Position: Q2 2026 in Review

HighVista Strategies reduced its MoonLake Immunotherapeutics (MLTX) stake by 3.1% in Q2 2026, selling an estimated $109K and leaving 187,946 shares worth $3.66M. The position accounts for 0.83% of the portfolio, ranked #39.

HighVista Strategies first reported a position in MLTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.62M in Q2 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

HighVista Strategies held 187,946 shares of MoonLake Immunotherapeutics worth $3.66M as of Q2 2026.
HighVista Strategies sold 6,009 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $109K.
MoonLake Immunotherapeutics made up 0.83% of HighVista Strategies's portfolio in Q2 2026, its #39 holding.
HighVista Strategies first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 13 quarters since.
HighVista Strategies's MoonLake Immunotherapeutics position peaked at $6.62M in Q2 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.